BRIANA TILLMAN: Open Payments
NPI 1619434545 · COLORADO SPRINGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$669 in 29 payments from 12 companies in 2025. Trend: 2023 $303 · 2024 $213 · 2025 $669
Food & beverage: $669
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 4 | $108 |
| ABBVIE INC. | 3 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Lundbeck LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: REXULTI, VRAYLAR, CAPLYTA, TRINTELLIX, Auvelity, ARISTADA, VIVITROL, AUSTEDO XR.
Industry payments across CO — which companies pay providers there.
